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Summary 1 
Background and purpose: It has been recently described that 5-HT4 receptor may be a target 2 
for antidepressant drugs. Here we have examined the effects of the dual antidepressant, 3 
venlafaxine, on 5-HT4 receptor-mediated signalling events. 4 
Experimental approach: The effects of 21 days-administration (p.o.) of high (40 mg kg-1) 5 
and low (10 mg kg-1) doses of venlafaxine, were evaluated at different levels of 5-HT4 6 
receptor-mediated neurotransmission by using in situ hibridization, receptor autoradiography, 7 
adenylate cyclase assays and electrophysiological recordings in rat brain. The selective 8 
noradrenaline reuptake inhibitor, reboxetine, (10 mg kg-1, 21 days) was also evaluated on 5-9 
HT4 receptor density. 10 
Key results: The administration of a high dose (40 mg kg-1) of venlafaxine did not alter 5-HT4 11 
mRNA expression, but resulted in a significant decrease in the density of 5-HT4 receptors in 12 
caudate-putamen (% reduction= 25.9 ± 5.6), hippocampus (% reduction=39.0 ± 6.8 and 39.0 13 
± 8.1 for CA1 and CA3, respectively) and substantia nigra (% reduction= 48.8 ± 4.5). 14 
Zacopride-stimulated adenylate cyclase activation was unaltered following the low dose 15 
treatment (10 mg kg-1) while it was attenuated in rats treated with 40 mg kg-1 of venlafaxine 16 
(% reduction= 50.6 ±1.5). Furthermore, the amplitude of population spike in pyramidal cells 17 
of CA1 of hippocampus induced by zacopride was significantly attenuated in rats receiving 18 
either dose of venlafaxine. Chronic reboxetine did not modify 5-HT4 receptor density. 19 
Conclusions and implications: Our data indicate a functional desensitization of 5-HT4 20 
receptors after chronic venlafaxine, similar to that observed with the classical SSRI drugs. 21 
Keywords: Venlafaxine, in situ hybridization, adenylate cyclase, electrophysiology, 5-HT4 22 
receptors. 23 
Abbreviations: relative optical density (R.O.D), 3’-5’-cyclic adenosine monophosphate 24 
(cAMP). 25 
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Introduction 1 
Multiple evidences support the idea that a deficit in serotonin and noradrenaline 2 
neurotransmission is associated with depression (Schildkraut, 1965; Coppen, 1967; Lanni et 3 
al. 2009). In line with this concept, effective treatment of the disease is achieved with 4 
monoaminooxidase inhibitors (MAOI), tricyclic antidepressants, selective serotonin reuptake 5 
inhibitors (SSRIs) or serotonin-noradrenaline reuptake inhibitors that enhance either central 6 
serotonin and/or noradrenaline neurotransmission (Vetulani and Nalepa, 2000; Schechter et 7 
al. 2005). This increase in serotonin and/or noradrenaline levels that occurs around 3-4 weeks 8 
after initiation of antidepressant treatment is mainly due to a functional desensitization of 9 
somatodendritic 5-HT1A autoreceptors and presynaptic α2 receptors located on serotonergic 10 
and noradrenergic neurons respectively (Blier and de Montigny 1994; Le Poul et al. 1995; 11 
Mateo and Meana 2001; Castro et al, 2003; Invernizzi and Garattini, 2004; Parini et al. 2005). 12 
In addition, other serotonin and noradrenaline receptors such as 5-HT2 and -adrenoceptors 13 
have also been implicated in depression and in the antidepressant mechanisms of action (see 14 
Brunello, 2002; Adell et al. 2005; Schechter et al. 2005). However, although it is well 15 
established that chronic antidepressants produce a considerable functional desensitization of 16 
these receptors as well as the reuptake serotonin and noradrenaline sites (Horschitz et al. 17 
2001; Benmansour et al. 2004; Nadgir and Malviya, 2008), the role of other serotonin 18 
receptors in the mechanisms of action of dual antidepressants remains still unexplored. 19 
Venlafaxine is a non selective serotonin-noradrenaline reuptake inhibitor that shows higher 20 
affinity for serotonin (5-HT) than for noradrenaline (NA) reuptake (Muth et al. 1986; Bolden-21 
Watson and Richelson, 1993). In fact, it has been described that at low doses, venlafaxine 22 
mainly acts as a 5-HT reuptake inhibitor alone whereas only at high doses are noradrenergic 23 
reuptake properties affected (Beique et al. 2000a, 2000b).  24 
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Focusing on serotonergic neurotransmission, 5-HT4 receptors are widely distributed in brain 1 
areas including basal ganglia, hippocampal formation, amygdala and cortex (Waeber et al. 2 
1994; Vilaró et al. 1996; Vilaró et al. 2005). These 5-HT4 receptors belong to the superfamily 3 
of G-protein coupled receptors which are positively coupled to adenylate cyclase (Hoyer et al. 4 
2002) promoting intracellular accumulation of cAMP. Activation of 5-HT4 receptors also 5 
inhibits potassium channels, thus contributing to the neuronal excitability of pyramidal cells 6 
of hippocampus (Andrade and Chaput 1991; Fagni et al. 1992). In central nervous system 5-7 
HT4 receptors appear to modulate neurotransmitter (acetylcholine, dopamine, serotonin and 8 
GABA) release and enhance synaptic transmission (Yamaguchi et al. 1997; Lucas and 9 
Debonnel, 2002; Bianchi et al. 2002; Alex and Pehek, 2007), and they may also play a role in 10 
memory, anxiety and depression (Bockaert et al. 2004, 2008; see King et al. 2008). 11 
Over the last few years, novel evidence indicates that 5-HT4 receptors may represent a new 12 
target for antidepressant drugs. First, an increase of 5-HT4 receptors in cortical and striatal 13 
areas was described in post-mortem depressed brain (Rosel et al. 2004). Second, it has been 14 
described that 5-HT4 receptors exert a facilitatory control on dorsal raphe nucleus 5-HT 15 
neuronal activity (Lucas et al. 2005) whereas knockout mice of these receptors show a 16 
reduction in this firing (Conductier et al. 2006).  Interestingly, it has recently been reported 17 
that two 5-HT4 partial agonists, RS67333 and SL65.0155, show antidepressant properties in a 18 
manner comparable with SSRIs with a faster onset of action (Lucas et al. 2007; Tamburella et 19 
al. 2009).   20 
Although two studies have recently shown that long-term treatment with both fluoxetine and 21 
paroxetine decrease 5-HT4 receptor density in the brain (Vidal et al. 2009; Licht et al. 2009), 22 
nothing is known about the regulation of this receptor by dual antidepressants. The goal of 23 
this study has been to evaluate the influence of chronic treatment with venlafaxine at different 24 
levels of the 5-HT4 transductional pathway by using in vitro procedures. For comparative 25 
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purposes, the effect of chronic reboxetine, a selective noradrenaline reuptake inhibitor 1 
(SNRI), on 5-HT4 receptor density was also analyzed. 2 
Methods 3 
Animals 4 
Male Wistar rats weighing 200-250g were group-housed and maintained at 21±1°C on 12/12 5 
h light/dark cycle, with access to food and water ad libitum. All experimental procedures were 6 
done according to the Spanish legislation and the European Communities Council Directive 7 
on “Protection of Animals Used in Experimental and Other Scientific Purposes” 8 
(86/609/EEC).  9 
Drug treatments 10 
Rats were orally administered by gavage with venlafaxine (10 mg kg-1 and 40 mg kg-1), 11 
reboxetine (10 mg kg-1) or saline once a day for 21 days. Drugs were administered at the same 12 
time each day, between 11 -12 h a.m., and twenty-four h after the last administration the 13 
animals were killed and their brains quickly removed: for in situ hybridization, 14 
autoradiographic and adenylate cyclase assays were frozen immediately in isopentane and 15 
then stored at -80C until use. For electrophysiological studies, brains were placed in artificial 16 
cerebrospinal fluid (see below). 17 
In situ hybridization 18 
Coronal sections of 20 m thickness were cut at -20C in a cryostat at the level of cortex, 19 
striatum and hippocampus according to the stereotaxic atlas of the rat brain (Paxinos and 20 
Watson, 1986). Sections were then thaw-mounted on slides and stored at -20C until use.  21 
Six different oligonucleotide probes were used simultaneously for the detection of 5-HT4 22 
receptor mRNA. They were complementary to the following bases of the rat 5-HT4 receptor 23 
mRNA (Gerald et al. 1995) (base numbering corresponds to the sequence of the 5-HT4(a) 24 
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splice variant, GenBank accession number U20906): 21-70, 258-307, 683-732, 741-790, 960-1 
1009, 1029-1078. These regions of the mRNA are common to all four C-terminal splice 2 
variants cloned in the rat: r5-HT4(a), r5-HT4(b) (Gerald et al. 1995), r5-HT4(e) (Claeysen et al. 3 
1999), and r5-HT4(c1) (Ray et al. 2009). Oligonucleotides were labeled at their 3'-end using 4 
[33P] α-dATP (111 TBq mmol-1, Perkin Elmer, Waltham, MA, USA) and terminal 5 
deoxynucleotidyltransferase (TdT) (Oncogene Research Products, San Diego, CA, USA). 6 
Labeled probes were purified from non-incorporated nucleotides with ProbeQuant G-50 7 
micro columns (GE Healthcare, Little Chalfont, UK). 8 
Tissues were treated before hybridization as described (Vilaró et al. 1992). They were air-9 
dried, fixed by immersion for 20 min in a solution of 4% paraformaldehyde in phosphate-10 
buffered saline (1 x PBS: 2.6 mM KCl, 1.4 mM KH2PO4, 136 mM NaCl, 8 mM Na2HPO4; pH 11 
7.5), washed once in 3 x PBS, twice in 1 x PBS, 5 min each, and incubated in a freshly 12 
prepared solution of predigested pronase (Calbiochem, San Diego, CA) at a final 13 
concentration of 24 U ml-1 in 50 mM Tris-HCl pH 7.5, 5 mM EDTA for 2 min at room 14 
temperature. Proteolytic activity was stopped by immersion for 30 s in 2 mg ml-1 glycine in 15 
PBS. Tissues were rinsed in PBS and dehydrated in a graded series of ethanol. For 16 
hybridization, labeled probes were diluted to a final concentration of approximately 2 x 107 17 
cpm ml-1 (0.3 nM each probe) in a solution containing 50% formamide, 4 x standard saline 18 
citrate (1 x SSC: 150 mM NaCl, 15 mM sodium citrate), 1 x Denhardt’s solution (0.02% 19 
Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin), 10% dextran sulfate, 1% 20 
Sarkosyl, 20 mM phosphate buffer pH 7.0, 250 g ml-1 yeast tRNA, 500 g ml-1 salmon 21 
sperm DNA (Vilaró et al. 1996). Tissues were covered with 70-80 l of hybridization 22 
solution, overlaid with Nescofilm coverslips (Bando Chemical, Inc., Kobe, Japan), and 23 
incubated overnight at 42°C. Sections were washed four times (45 min each) in 600 mM 24 
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NaCl, 10 mM Tris-HCl pH 7.5, 1 mM EDTA at 60°C, dehydrated and exposed to film 1 
(Biomax-MR, Kodak) for 2-3 weeks at -70°C. 2 
3HGR113808 receptor autoradiography 3 
Sections were then thaw-mounted in gelatinized slides and stored at -20C until use. 5-HT4 4 
receptor autoradiography was performed as previously reported by Waeber et al. (1994) using 5 
the 5-HT4 antagonist 3HGR113808 as radioligand. Tissue sections, obtained as above, were 6 
preincubated at room temperature for 15 min in 50 mM Tris-HCl buffer (pH 7.5) containing 7 
CaCl2 4 mM and ascorbic acid (0.1%). Sections were then incubated, at room temperature for 8 
30 min, in the same buffer with 0.2 nM 3HGR113808. Non-specific binding was determined 9 
using 10 M 5-hydroxytryptamine. After incubation, sections were washed for 30 s in ice-10 
cold buffer, briefly dipped in deionized water at 4ºC, and then cold air-dried. Autoradiograms 11 
were generated by apposing the slides to Biomax MR film sheets (Kodak, Madrid, Spain) 12 
together with tritium labeled standards for 6 months at 4C. 13 
Adenylate cyclase assay 14 
5-HT4 stimulated adenylate cyclase procedure was carried out as previously described by 15 
Vidal et al. (2009). Frozen brain striata were homogenized (1:120 W/V) in 20 mM Tris-HCl, 16 
2 mM EGTA, 5 mM EDTA, 320 mM sucrose, 1 mM dithiothreitol (DTT), 25 g ml-1 17 
leupeptin, pH 7.4 and centrifuged at 500 x g for 5 min at 4C. The supernatants were pelleted 18 
at 13000 x g for 15 min at 4C and resuspended in 20 mM Tris-HCl, 1.2 mM EGTA, 0.25 M 19 
sucrose, 6 mM MgCl2, 3 mM DTT and 25 g ml-1 leupeptin. The membranes were used 20 
immediately after preparation. 21 
Membrane suspensions were pre-incubated for 15 min on ice in reaction buffer (75 mM Tris-22 
HCl pH 7.4, 5 mM MgCl2, 0.3 mM EGTA, 60 mM sucrose, 1 mM DTT, 0.5 mM 3-23 
isobutylmethylxanthine, 5 mM phosphocreatine, 50 U ml-1 creatine phosphokinase and 5 U 24 
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ml-1 myokinase) and 25 l of either water (basal activity) or zacopride (10-3 M- 10-8 M). The 1 
reaction was started by the addition of 0.2 mM Mg-ATP and incubated at 37ºC for 10 min 2 
The reaction was stopped by boiling the samples in water for 4 min and then centrifuged at 3 
13,000 g for 5 min at 4ºC. cAMP accumulation was quantified in 50 l aliquots of supernatant 4 
by using a [3H]cAMP commercial kit, based on the competition of a fixed amount of 5 
[3H]cAMP and the unlabelled form of cAMP for a specific protein, achieving the separation 6 
of protein-bound nucleotide by adsorption on coated charcoal. (TRK 432, Amersham 7 
Pharmacia Biotech U.K. Limited, Buckinghamshire, UK). Membrane protein concentrations 8 
were determined using the Bio-Rad Protein Assay Kit (Bio-Rad, Munich, Germany) using -9 
globulin as the standard. 10 
Hippocampal slice preparation and extracellular recording 11 
After decapitation, the brain was quickly removed and placed in an artificial cerebrospinal 12 
fluid (ACSF) consisting of 124 mM NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 1 mM MgSO4, 2 13 
mM CaCl2, 26 mM NaHCO3 and 10 mM glucose. Transverse slices, 400 m-thick, from 14 
hippocampus were obtained using a tissue slicer and were left to recover in ACSF for 1h. A 15 
single slice was transferred to a recording chamber and continuously superfused at a rate of 1 16 
ml min-1 with ACSF saturated with 95% O2, 5% CO2 and maintained at 30ºC. For 17 
extracellular recording of population spikes, a glass microelectrode filled with 3 M NaCl (1 - 18 
4 M) was positioned in the stratum pyramidalis of the CA1 area. A bipolar, tungsten 19 
electrode was placed in the stratum radiatum for stimulation of the Schaffer collateral-20 
commissural pathway. Pulses of 0.05 ms duration were applied at a rate of 0.05 Hz. The 21 
population spike signals were amplified, bandpass-filtered (1Hz-1kHz) and stored in a 22 
computer using the Spike 2 program (Spike2, Cambridge Electronic Design, Cambridge, 23 
UK). On the basis of other studies (Tokarski and Bijak 1996; Bijak et al. 1997) half-24 
maximum stimulation intensity was chosen to evaluate the effect of zacopride. After 25 
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stabilization of the baseline response for at least 1 h (defined as no more than 10% variation 1 
in the median amplitude of the population spike or stable membrane potential), the slice was 2 
superfused for 10 min with zacopride (10 M). Each slice in the extracellular recording was 3 
treated as an independent sample. 4 
Data analysis 5 
Autoradiograms were analyzed and quantified (radioligand autoradiography) or semi-6 
quantified (in situ hybridization) using a computerized image analysis system (Scion Image, 7 
Scion Corporation, Maryland, USA). In electrophysiological records, the effect of zacopride 8 
is expressed as mean (± SEM) percentage change of the baseline (predrug). Emax and ED50 9 
values in both adenylate cyclase assays and electrophysiological recordings were calculated 10 
using the program GraphPad Prism program (GraphPad Software 1998). The statistical 11 
analysis of the results obtained following venlafaxine administration was performed using 12 
Student t-test for in situ hybridization or one-way ANOVA followed by post hoc comparisons 13 
(Student Newman-Keuls test). Results from reboxetine administration (5-HT4 receptor 14 
autoradiography) were analyzed by Student t-test. P < 0.05 was considered statistically 15 
significant. 16 
Drugs and chemical reagents  17 
All drugs and receptors nomenclature conforms to Alexander et al. (2008). [33P] α-dATP (111 18 
TBq mmol-1) was purchased from Perkin Elmer (Waltham, MA, USA). 3HGR113808 19 
(specific activity 3.07 TBq mmol-1) was purchased from Amersham and venlafaxine-HCl and 20 
reboxetine were kindly donated by FAES-Farma. 5-Hydroxytrytamine hydrochloride was 21 
purchased from Sigma-Aldrich (Madrid, Spain). 4-amino-5-chloro-2-methoxy-substituted 22 
benzamide (R,S) zacopride (zacopride) was obtained from RBI (Madrid, Spain). All other 23 
 10
chemicals used were of analytical grade. Venlafaxine and reboxetine were dissolved in saline 1 
(0.9%) and given by oral administration (p.o.) in a volume of 5 ml kg-1 body weight. 2 
 3 
Results 4 
Effect of chronic venlafaxine in mRNA 5-HT4 expression  5 
A specific distribution of the mRNA encoding for 5-HT4 receptors was observed through 6 
different structures of the rat brain, in good agreement with previous studies. In vehicle 7 
treated rats, strong hybridization signals were observed in the hippocampus (film relative 8 
optical density (R.O.D.) = 80-135) and basal ganglia (R.O.D. = 35-55). Intermediate signals 9 
were also detected in superior colliculus whereas 5-HT4 receptor mRNA expression in the 10 
frontal cortex was only moderately labelled (Figure 1). As shown in Figure 2, chronic 11 
administration of venlafaxine (40 mg kg-1 p.o.) had no effect on 5-HT4 mRNA expression at 12 
24 h after the last administration of the antidepressant in any of the brain regions measured: 13 
frontal cortex, striatum or hippocampus. 14 
Effect of chronic antidepressants on the density of 5-HT4 receptors 15 
To evaluate whether treatment with venlafaxine and reboxetine affects the density of 5-HT4 16 
receptors we measured the binding of the antagonist radioligand 3HGR113808 in rat brain 17 
sections. Only the high dose of venlafaxine tested produced a significant decrease in the 18 
density of 5-HT4 receptors in caudate-putamen (% reduction = 25.9 ± 5.6; P < 0.01), 19 
hippocampus (% reduction = 39.0 ± 6.8 % and 39.0 ± 8.1, for CA1 (P < 0.01) and CA3 (P < 20 
0.01), respectively and substantia nigra (% reduction = 49.8 ± 4.5; P < 0.01) when compared 21 
to vehicle treated rats. In contrast, neither dose of venlafaxine modified the density of 5-HT4 22 
receptors in the frontal cortex (Table 1 and Figure 3). On the other hand, chronic reboxetine 23 
did not alter 5-HT4 receptor binding in any of the brain areas analyzed (Table 2). 24 
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Effect of chronic venlafaxine in zacopride induced cAMP accumulation in rat striatum 1 
Chronic venlafaxine did not alter the basal cAMP levels in rat striatum membranes although a 2 
tendency to the increase was observed after the dose of 40 mg kg-1 (10.5 ± 3.0 and 17.5 ± 1.8 3 
pmol min-1 mg protein-1, for vehicle and venlafaxine respectively). As shown in figure 4, the 4 
agonist zacopride induced a concentration-dependent increase in cAMP production in the 5 
vehicle group, with EC50 = 2.9 ± 1.1 M and an Emax = +45.9 ± 0.7 % of stimulation over the 6 
basal value (100%). The treatment with the high dose of venlafaxine, administered for 21 7 
days, induced a marked suppression of zacopride-stimulated cAMP accumulation yielding an 8 
Emax = +22.0 ± 1.4 (P < 0.05 vs vehicle). This reduction in the efficacy was also accompanied 9 
with an increase in EC50 (27 ± 1.2 M). Nevertheless, chronic administration of venlafaxine 10 
at the dose of 10 mg kg-1 did not significantly alter the cAMP accumulation induced by 11 
zacopride (Figure 4). 12 
Effect of chronic venlafaxine on population spikes of CA1 field 13 
According to previous reports from our group, the selective 5-HT4 agonist zacopride induced 14 
a concentration-dependent increase of the population spike amplitude in the hippocampal 15 
CA1 field evoked by Schaffer collateral stimulation with a potency in the M order (Vidal et 16 
al. 2009). Taking into account this observation, we evaluated the effect of chronic treatment 17 
with venlafaxine on the stimulation of population spike induced by 10 M zacopride. The 18 
effect of the application of zacopride was significantly reduced in slices obtained from rats 19 
treated with venlafaxine 10 mg kg-1 (% reduction = 36.7 ± 7.6; P < 0.05). This decrease was 20 
even more pronounced with the dose of 40 mg kg-1 (% reduction =55.5 ± 12.2; P < 0.01) 21 
(Figure 5). 22 
 23 
 24 
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Discussion and conclusions 1 
Dual antidepressant drugs affect both the serotonergic and noradrenergic systems by inducing 2 
adaptive changes in several receptor subtypes in the brain. In the present study, we have found 3 
that a 21-days treatment with 40 mg kg-1 of venlafaxine (high dose), leads to a down-4 
regulation of 5-HT4 receptor density without altering mRNA expression. It also results in an 5 
attenuation of zacopride-stimulated adenylate cyclase system. In contrast, 10 mg kg-1 (low 6 
dose) has no significant effect on these neurochemical markers. Furthermore, both doses of 7 
this antidepressant induce a desensitization of 5-HT4 receptors in hippocampus evaluated by 8 
electrophysiological recordings of the neuronal activity controlled by this receptor subtype. 9 
Our results following chronic venlafaxine are in contrast with those obtained with the SNRI 10 
reboxetine, in which no significant modification of 5-HT4 receptor density was observed after 11 
its chronic administration. 12 
To our knowledge this is the first preclinical report evaluating the modulation of the 13 
signalizing cascades linked to 5-HT4 receptors following a treatment with a 5-HT/NE dual 14 
reuptake inhibitor, venlafaxine. The present data show a down-regulation of 5-HT4 receptors 15 
in striatum and hippocampus while the density in frontal cortex remains unaltered. This 16 
desensitization may not be explained by a direct effect of the drug since venlafaxine 17 
(Bymaster et al. 2001; Artaiz et al. 2005) does not show a direct affinity for 5-HT4 receptors 18 
(Bymaster et al. 2001). These findings are in accordance with several data previously reported 19 
after long term administration of another class of antidepressants, SSRI drugs, including 20 
fluoxetine (Vidal et al. 2009) and paroxetine (Licht et al. 2009). In contrast, Gobbi et al. 21 
(1997) failed to detect any significant changes on 5-HT4 receptor density after chronic 22 
citalopram in substantia nigra.  23 
It is important to note that 5-HT4 mRNA expression remains unaltered by chronic 24 
venlafaxine. Taking into account this fact, it is unlikely that the down-regulation of 5-HT4 25 
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receptors found in our study is a result of an alteration in the synthesis process. The most 1 
feasible explanation indicates that this down-regulation reflects internalization and/or 2 
increased degradation as a consequence of prolonged exposure to either 5-HT or NE after 3 
chronic no selective serotonin and noradrenaline reuptake drugs. However, we cannot discard 4 
possible changes in 5-HT4 receptor affinity after chronic venlafaxine since we have used an 5 
antagonist as radioligand, thus recognizing with a similar affinity the different affinity states 6 
of the receptor. Further studies with an agonist radioligand should be carried out in order to 7 
clarify this point. 8 
It is well known that the regulation of serotonin receptors depends on several factors 9 
including brain area expression (Castro et al. 2003), signalling pathway (Berg and Clarke, 10 
2001) or type of agonist used to evaluate the functional responses (Valdizan et al. 2009). 11 
Similar to previous reports regarding chronic SSRIs (Vidal et al. 2009; Licht et al. 2009) the 12 
down-regulation of 5-HT4 receptor induced by venlafaxine is region-dependent. As 13 
mentioned above, we found that the density of the receptor in medial prefrontal cortex 14 
remains unaltered by long term treatment with venlafaxine. Indeed, this differential regulation 15 
of 5-HT4 receptors may be due to the higher density of 5-HT uptake sites observed in the 16 
hippocampus compared to the frontal cortex (Hrdina et al. 1990 and personal observation). 17 
Furthermore, the lack of down-regulation of 5-HT4 receptors observed in frontal cortex could 18 
also be interpreted in the context of recent works suggesting that cortical 5-HT4 receptors 19 
contribute to increase the firing activity of 5-HT neurons (Lucas and Debonnel, 2002; Lucas 20 
et al. 2005). The evidence of opposite changes in 5-HT4 receptor density (up-regulation) 21 
observed in frontal cortex and striatum in depressed suicide victims (Rosel et al. 2004) 22 
corroborates the relevance of our findings.  23 
In the last few years, the interest about the mechanisms of action of antidepressants has 24 
moved from the receptor level to the intracellular signaling cascades. Thus, one element that 25 
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is receiving special interest in depression as well as in the mechanism of action of 1 
antidepressant drugs is the adenylate cyclase system (Dowlatshahi et al. 1999; Valdizan et al. 2 
2003; Donati and Rasenick, 2003). In this work we have found that long term venlafaxine 3 
administration leads to a functional desensitization of striatal 5-HT4 receptors measured as 4 
zacopride-induced accumulation of cAMP without changes in the basal levels. Interestingly 5 
only the 40 mg kg-1 dose of chronic venlafaxine induces desensitization of striatal 5-HT4 6 
receptors while a lower dose had no effect. Thus, the modification on the sensitivity of this 7 
second messenger pathway could be attributable to the decrease in 5-HT4 receptor density in 8 
striatum observed only at 40 mg kg-1 dose of venlafaxine. In addition, the decreased capacity 9 
of zacopride to induce accumulation of cAMP in the striatum may be also attributed to 10 
regulatory changes at the level of the G protein such as a decrease in the efficacy of coupling 11 
between the receptor and the heterotrimeric GS-protein in response to receptor activation. In 12 
fact by using [35S]GTPS experimental procedures several studies have reported, for other 13 
serotonin receptors, a desensitization at this coupling level after chronic antidepressants 14 
(Hensler, 2002; Pejchal et al. 2002; Castro et al. 2003). Unfortunately, experimental 15 
limitations of the technique do not allow to visualize the specific activation of G proteins for 16 
Gs-coupled receptors. 17 
The last decade of research on the mechanisms implicated in depression has lead to the 18 
accumulation of a large number of evidences supporting the idea that the hippocampus may 19 
play an important role in this disease (see Frodl et al. 2008) and in the mechanism of action of 20 
antidepressant drugs (Duman et al. 2001; Drew and Hen, 2007; Mostany et al. 2008). In this 21 
regard, the electrophysiological recordings also indicate that chronic venlafaxine modifies, in 22 
a dose-dependent way, the sensitivity of postsynaptic 5-HT4 receptors in the hippocampus as 23 
illustrated by an attenuation of zacopride-induced increase of the amplitude of population 24 
spike. The most plausible explanation for these results is that 5-HT4 receptor desensitization 25 
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may be a direct consequence of the decrease in 5-HT4 receptor density in hippocampus. 1 
However, this functional desensitization was also observed after the administration of 10 mg 2 
kg-1 of venlafaxine, a treatment that did not result in a significant modulation of 5-HT4 3 
receptor density. This fact suggests the involvement of other mechanisms, in addition to the 4 
modifications of the level of expression of the protein. In this way, similar findings have been 5 
reported after prolonged treatment with SSRIs in the regulation of other 5-HT receptors 6 
subtypes. Thus, the desensitization of 5-HT1A autoreceptors by chronic SSRIs (Blier and de 7 
Montigny 1994; Le Poul et al. 1995) takes place downstream the receptor protein, in the 8 
intracellular signalling cascades without changes in the receptor density (Hervás et al. 2001; 9 
Hensler, 2002; Castro et al. 2003, 2008).  10 
On the other hand, in vitro and in vivo experiments in hippocampus using the same dose 11 
regimen of venlafaxine have shown a functional desensitization of the terminal 5-HT1B 12 
autoreceptor after high but not low doses of chronic antidepressant (Beiqüe et al. 2000a, 13 
2000b). Although the degree of modulation of 5-HT extracellular levels in hippocampus after 14 
chronic venlafaxine (40 mg kg-1) has not been reported yet, one could speculate that the 15 
desensitization of 5-HT1B autoreceptors observed after 40 mg kg-1 dose leads to higher 16 
synaptic 5-HT levels compared to 10 mg kg-1 dose. Thus, this may account for the dose-17 
dependent venlafaxine-induced desensitization of 5-HT4 receptors as a more marked 18 
attenuation was observed following administration of a high dose of venlafaxine. In line with 19 
our findings, using the same paradigm some authors indicate that chronic SSRIs (imipramine, 20 
citalopram, fluoxetine) as well as repeated electroconvulsive shock also result in 5-HT4 21 
receptor desensitization in pyramidal cells of CA1 of hippocampus (Bijak et al. 1997; Bijak et 22 
al. 2001; Vidal et al. 2009).  23 
The higher dose of venlafaxine (40 mg kg-1) used in our study has been reported to modify 24 
NE uptake (Beicque et al. 2000a, b): in this regard, although data about NE extracellular 25 
 16
levels after this treatment are not currently available, an elevation in NE levels in frontal 1 
cortex has been reported following administration of a lower dose (10 mg kg-1) of the drug 2 
(Millan et al. 2001). Interestingly, our results on the modulation of 5-HT4 receptors by 40 mg 3 
kg-1 of venlafaxine are quite similar to those previously reported for the chronic 4 
administration of fluoxetine (Vidal et al. 2009), an antidepressant which does not affect NE 5 
neurotransmission. Then, it could be suggested that the noradrenergic component of 6 
venlafaxine does not play a relevant role in the changes induced on 5-HT4 receptors 7 
functionality. Our results showing a lack of modifications on receptor density following 8 
chronic reboxetine (Invernizzi et al. 2001; Parini et al. 2005) further support that the changes 9 
seen with venlafaxina are mainly due to modifications in 5-HT neurotransmission. 10 
Our results, and those from other studies (Vidal et al. 2009), showing a clear regulation of 5-11 
HT4 receptors following chronic treatment with antidepressants, are of special interest in view 12 
of the recent identification of these receptors as a direct target for a short-onset treatment of 13 
depression: it has been proposed that a 3-days treatment with the 5-HT4 agonist RS67333 14 
induces some antidepressant-like behavioural responses in animals (Lucas et al. 2007). In this 15 
regard, data from our laboratory suggest that a short-term treatment with this agonist also 16 
results in neuroplastic and neuroproliferative changes (i.e. increase in BrdU incorporation in 17 
dentate gyrus of hippocampus, increased expression of BDNF) quite similar to those observed 18 
after 2-3 weeks treatment with classical antidepressants (Pascual-Brazo et al. 2009). 19 
Taken together these results indicate an important role of 5-HT4 receptors in the mechanism 20 
of antidepressant responses. The desensitization observed in our study, also reported for 21 
SSRIs and electroconvulsive shock, is probably a consequence of the sustained increase in 5-22 
HT levels induced by antidepressants, which would result in the normalization of serotonergic 23 
neurotransmission in the depressed patient. Whether or not the desensitization of 5-HT4 24 
 17
receptors is also present after the short-term “antidepressant” administration of 5-HT4 agonists 1 
remains to be clarified. 2 
 In summary, long term treatment with venlafaxine results in regulatory changes in 5-HT4 3 
signalling pathway particularly in striatum and hippocampus similar to those observed after 4 
SSRIs. These changes appear to be mainly dependent on the increase in 5-HT levels. 5 
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Tables 1 
 2 
 3 
Table 1. Effect of chronic venlafaxine on the specific [3H]GR113808 binding in coronal 4 
sections (20 μm) of rat brain.  5 
 6 
Area 
Vehicle 
 
(10-12) 
Venlafaxine 
(10 mg kg-1 day-1) 
(7) 
Venlafaxine 
(40 mg kg-1 day-1) 
(6) 
Medial Prefrontal 
cortex 13.0 ± 1.1 12.7 ± 0.7 11.2 ± 1.3 
Caudate-Putamen 18.1 ± 0.6 17.9 ± 1.0 13.9 ± 1.1*+ 
Globus Pallidus 17.2 ± 0.9 15.9 ± 0.9 12.8 ± 1.2* 
CA1 14.7 ± 0.8 15.1 ± 0.6 8.9 ± 1.0**++ 
CA3 14.2 ± 1.0 13.7 ± 0.5 8.7 ± 1.2**++ 
Substantia nigra 14.6 ± 0.9 13.9 ± 0.6 7.4 ± 0.7**++ 
 7 
Values are expressed as the mean ± S.E.M of Bmax (fmol mg-1 tissue) considering a KD value 8 
of [3H]GR113808 0.2 nM. The number of determinations is shown in parenthesis, in each 9 
column heading. *P < 0.05; **P < 0.01 versus vehicle and +P <0.05; ++P < 0.01 versus 10 mg 10 
kg-1 venlafaxine treated rats. One-way ANOVA followed by Student Newman-Keuls test. 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 26
Table 2. Effect of chronic reboxetine on the specific [3H]GR113808 binding in coronal 1 
sections of rat brain.  2 
 3 
Area Vehicle (10-12) 
Reboxetine 
(10 mg kg-1 day-1) 
(7) 
Medial Prefrontal 
cortex 13.9 ± 0.5 12.7 ± 0.8 
Caudate-Putamen 18.8 ± 0.8 18.5 ± 0.9 
Globus Pallidus 17.3 ± 0.5 16.7 ± 0.8 
CA1 15.7 ± 0.9 15.2 ± 1.0 
CA3 15.3 ± 0.9 14.6 ± 1.0 
Substantia nigra 14.8 ± 0.7 13.9 ± 0.7 
 4 
Values are expressed as the mean ± S.E.M of Bmax (fmol mg-1 tissue). The number of 5 
determinations is shown in parenthesis, in each column heading.  6 
 7 
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Figure 1. Representative autoradiograms showing the 5-HT4 receptor mRNA distribution in 1 
coronal sections of rats chronically treated with vehicle. mPFCx: medial prefrontal cortex; 2 
CPu: caudate-putamen; VP: ventral pallidum; GP: globus pallidus; CA1: CA1 field of 3 
hippocampus; CA3: CA3 field of hippocampus; DG: dentate gyrus; S: subiculum; SuG: 4 
superior colliculus. Bar: 2 mm.  5 
 6 
 7 
Figure 2. Effect of chronic venlafaxine on 5-HT4 mRNA levels in rat brain measured as 8 
relative optical density (R.O.D.). R.O.D for background tissue signal was 47.16. mPFCx: 9 
medial prefrontal cortex; CPu: caudate-putamen; GP: globus pallidus; VP: ventral pallidus; 10 
CA1: CA1 field of hippocampus; DG: dentate gyrus of hippocampus; CA3: CA3 field of 11 
hippocampus; S: subiculum; SuG: superior colliculus. No significant differences were found 12 
between both experimental groups (Student t-test, unpaired data; n = 7 rats per group).  13 
 14 
 15 
Figure 3.  Representative autoradiograms of [3H]GR113808 binding in rats chronically 16 
treated with vehicle (left), venlafaxine 10 mg kg-1 (middle) and venlafaxine 40 mg kg-1 (right) 17 
in coronal sections of frontal cortex, striatum and hippocampus. mPFCx: medial prefrontal 18 
cortex; CPu: caudate-putamen; CA1: CA1 field of hippocampus, CA3: CA3 field of 19 
hippocampus. Bar: 2 mm. 20 
 21 
Figure 4. Concentration-response curves showing the effect of chronic venlafaxine on 22 
zacopride-induced accumulation of cAMP (expressed as mean ± SEM of the percentage of 23 
increase over basal values) in striatum membranes from vehicle and venlafaxine-treated rats. 24 
Emax: *P < 0.05 significantly different from vehicle-treated group by Student Newman-Keuls 25 
post hoc test. Six rats per experimental group were included.  26 
 27 
 28
Figure 5. Left: Effect of repeated treatment with venlafaxine on the stimulatory action of 1 
zacopride on population spike amplitude. A population spike which was 50% of the 2 
maximum amplitude was chosen. **P < 0.01; *P < 0.05 vs vehicle treated group (One-way 3 
anova and Student Newman-Keuls post hoc test). (n = 8, 6 and 7 animals for vehicle, 4 
venlafaxine 10 and 40 mg kg-1 day-1, respectively). Right: Electrophysiological recordings of 5 
pyramidal cells during the perfusion of 10 M zacopride after stimulation of the Schaffer 6 
collateral-commissural pathway in vehicle and venlafaxine-treated group. The arrow indicates 7 
the stimulus artifact. 8 
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